Phase I study of mitozolomide on a once daily for 5 days schedule.

Autor:	Schornagel, Jan, Simonetti, Godelaine, Dubbelman, Ria, Huinink, Wim, McVie, J., Schornagel, J H, Simonetti, G, Dubbelman, R, ten Bokkel Huinink, W W, McVie, J G
Předmět:	ANTINEOPLASTIC agents BLOOD cells BONE marrow CLINICAL trials DOSE-effect relationship in pharmacology CLINICAL drug trials NITROGEN mustards TIME TUMORS
Zdroj:	Cancer Chemotherapy & Pharmacology; Jun1990, Vol. 26 Issue 3, p237-238, 2p
Abstrakt:	In a phase I study mitozolomide was given on a once daily for 5 days schedule to 18 patients with a variety of malignancies. Non-hematological toxicity was negligible. Significant myelosuppression occurred at a total dose as low as 62.5 mg/m2 per course. In particular, thrombocytopenia, which was unpredictable, precluded dose increments beyond 15 mg/m2 per day (or a total of 75 mg/m2). Antitumor effects were not observed. The 5-day schedule of mitozolomide appears to have no advantage over administration once every 3-4 weeks, and may even be more dangerous than the latter schedule. [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Full text from SpringerLink